Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
OTCMKTS:DGNOF

DIAGNOS Q2 2026 Earnings Results & Report

DIAGNOS logo
$0.28 0.00 (-0.39%)
As of 10/15/2026 03:52 PM Eastern

DIAGNOS reported Q2 2026 earnings on November 20, 2025. The company reported EPS of -$0.01, while revenue was $0.01 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
During Market Hours

DIAGNOS EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DIAGNOS Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

DIAGNOS' next earnings date is estimated for Tuesday, December 1, 2026, based on past reporting schedules.

Conference Call Resources

DIAGNOS Q2 2026 Earnings FAQ

DIAGNOS (OTCMKTS:DGNOF) reported earnings of -$0.01 per share for Q2 2026. The report was announced on Thursday, November 20, 2025.

DIAGNOS reported revenue of $0.01 million for Q2 2026.

DIAGNOS' next earnings date is estimated for Tuesday, December 1, 2026. MarketBeat tracks confirmed and estimated earnings dates for DIAGNOS on the company's earnings history page.

DIAGNOS Earnings Headlines

DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3370104/0/en/diagnos-advances-regulatory-strategy-with-us-fda-submission-for-cara-system.html
DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361404/0/en/diagnos-to-hold-its-annual-general-meeting-of-shareholders-on-september-30-2026.html
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
 |  American Alternative (Ad)
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344835/0/en/diagnos-receives-saudi-fda-medical-device-license-for-cara-system-bringing-ai-assisted-retinal-image-analysis-to-saudi-arabia.html
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333833/0/en/diagnos-receives-health-canada-medical-device-licence-for-cara-system-bringing-ai-assisted-retinal-image-analysis-to-canadian-optometrists.html
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/05/3307455/0/en/emerging-growth-research-releases-flash-report-on-diagnos-highlighting-regulatory-catalysts-and-commercialization-potential-for-cara-ai-platform.html
See More DIAGNOS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DIAGNOS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DIAGNOS and other key companies, straight to your email.

About DIAGNOS

DIAGNOS (OTCMKTS:DGNOF) is a Canadian healthcare technology company focused on using artificial intelligence to support the early detection and screening of diseases. The company develops and deploys computer-assisted diagnostic tools designed to help healthcare professionals analyze medical images and identify potential health conditions.

Its primary technology platform, CARA, is used for the analysis of retinal images. DIAGNOS has applied the platform to screening for eye-related conditions, including diabetic retinopathy, and has also explored applications involving other diseases and medical imaging use cases. The company provides technology and screening services to healthcare providers, organizations and patients.

DIAGNOS has historically operated screening programs and pursued commercial relationships in Canada and international markets. Its business combines the development of artificial intelligence software with the delivery of diagnostic screening services, with an emphasis on expanding access to early detection in communities that may have limited access to specialized healthcare.

View DIAGNOS Profile
Earnings Tools